NAMD
Clinical trials for NAMD explained in plain language.
Never miss a new study
Get alerted when new NAMD trials appear
Sign up with your email to follow new studies for NAMD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New eye implant could cut injections from monthly to twice a year for wet AMD patients
Disease control Recruiting nowThis study tests a small implant placed in the eye that releases medication slowly, so patients need treatment only every 24 weeks instead of every 4 weeks. It involves 68 Chinese adults with wet age-related macular degeneration who have already responded to standard injections. …
Matched conditions: NAMD
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 26, 2026 09:13 UTC
-
One shot to save sight? gene therapy trial aims to end monthly eye injections
Disease control Recruiting nowThis Phase 3 study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single treatment can control the disease as well as standard eye injections given every few months. About 714 ad…
Matched conditions: NAMD
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated May 26, 2026 09:02 UTC
-
New eye drug shows promise for blinding disease
Disease control Recruiting nowThis study tests a new medicine called SCT520FF for people with wet age-related macular degeneration (nAMD), a condition that can cause vision loss. The trial will include 82 adults aged 45 to 80 to check the drug's safety and how well it works. The goal is to control the disease…
Matched conditions: NAMD
Phase: PHASE1, PHASE2 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated May 18, 2026 12:00 UTC